Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent Advocacy Hub | UniteRare

At a Glance

Live from database

Regulatory Watchboard

10 events

Dec 2027A Phase 1b/2 Open-label, Dose-ranging Safety and Efficacy Study of Oral Cladribine in Patients With Acute Myeloid Leukemia (AML)

M.D. Anderson Cancer Center — PHASE1, PHASE2

TrialNOT YET RECRUITING

Dec 2026FLT3-ITD Targeted Therapy in Fit AML Patients

European Organisation for Research and Treatment of Cancer - EORTC — PHASE2, PHASE3

TrialNOT YET RECRUITING

Oct 2026Comparing Different Treatment Lengths for Venetoclax in Older People With Newly Diagnosed Acute Myeloid Leukemia (A MyeloMATCH Treatment Trial)

National Cancer Institute (NCI) — PHASE2

TrialNOT YET RECRUITING

Aug 2026Phase 1/1b Trial Of Olutasidenib And Ziftomenib For NPM1 And IDH1 Co-Mutated Acute Myeloid Leukemia

M.D. Anderson Cancer Center — PHASE1

TrialNOT YET RECRUITING

May 2026High-dose Ascorbate (HDA) in Combination With Standard of Care Azacitidine and Venetoclax in Acute Myeloid Leukemia (AML)

Kittika Poonsombudlert — PHASE1

TrialNOT YET RECRUITING

May 2026Study of an Innovative Therapy Using CAR-T Cells Targeting IL-1RAP in Patients With High-Risk Myelodysplastic Syndromes (MDS

University Hospital, Grenoble — NA

TrialNOT YET RECRUITING

Apr 2026Pacritinib, a Kinase Inhibitor of CSF1R, IRAK1, JAK2, and FLT3, in Adults and Pediatric Participants 12 Years of Age or Older With Myelodysplastic Syndromes or Myelodysplastic/Myeloproliferative Neoplasms

National Cancer Institute (NCI) — PHASE1, PHASE2

TrialRECRUITING

Apr 2026A Study to Compare Elritercept With Epoetin Alfa to Treat Anemia in Adults With Very Low, Low, or Intermediate Risk Myelodysplastic Syndromes (MDS) Who Need Regular Blood Transfusions

Takeda — PHASE3

TrialRECRUITING

Apr 2026A Single-arm, Prospective Study of a Cladribine-Bridged LABU Conditioning Regimen in Allogeneic Hematopoietic Stem Cell Transplantation for Relapsed/Refractory MDS/AML in Elderly Patients

The First Affiliated Hospital of Soochow University — NA

TrialRECRUITING

Apr 2026Phase I/II Clinical Trial of Universal Donor CD33 CAR Natural Killer Cells for AML

Nationwide Children's Hospital — PHASE1, PHASE2

TrialNOT YET RECRUITING

Data from FDA regulatory filings and ClinicalTrials.gov. Updated periodically.

Financial Assistance

FINANCIAL LANDSCAPE SUMMARY

Total programs

No financial assistance programs currently listed for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent.
Check the disease page for updates →

Clinical Trial Landscape

131 active trials

8Phase 3

2Phase 4

37Phase 2

43Phase 1

12N/A

10Unknown

11PHASE1, PHASE2

6EARLY_PHASE1

2PHASE2, PHASE3

131Total recruiting

Search clinical trials for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent →

Recent News & Research

No recent news articles indexed yet for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent.
Search PubMed for Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent →

Browse all Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent news →

Specialist Network

Top 6 by expertise

Hagop Kantarjian, MD, MD

M.D. Anderson Cancer Center

📍 HOUSTON, TX

Score 397 trials

Global Clinical Leader

Daiichi Sankyo

Score 3644 trials4 pubs

Olivier Hermine, MD

Assistance Publique - Hôpitaux de Paris

Score 353 trials

Naval Daver, MD, MBBS

M.D. Anderson Cancer Center

📍 HOUSTON, TX

Score 308 trials

Farhad Ravandi-Kashani, MD, M.D

M.D. Anderson Cancer Center

📍 HOUSTON, TX

Score 198 trials

Jorge Cortes, MD

UT MD Anderson Cancer Center

Score 1917 trials

View all Acute myeloid leukemia and myelodysplastic syndromes related to alkylating agent specialists →

Quick Actions

📄

View Disease Page

Full profile, treatments, community

🔬

Search Clinical Trials

Find recruiting studies now

🩺

Find Specialists

Ranked by expertise & trials

💰

Financial Assistance

Copay cards, PAPs, grants

📰